Bias related to funding source in statin trials: The biases are clear if you know where to look

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Bero, Lisa ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; DRUG ADMINISTRATION ROUTE; DRUG COMPETITION; DRUG DOSE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FUNDING; INDUSTRY BIAS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC ERROR;

EID: 84907661955     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5949     Document Type: Editorial

References (13)

1. Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014;349:g5741.
2. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLOS Med 2007;4:e184.
3. Kelley C, Helfand M, Good C, Ganz M. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Drug class review: Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins). 2002. www.pbm.va.gov/clinicalguidance/drugclassreviews/hmgcoareductaseinhibitorsstatinsdrugclassreviewandappendices.pdf.
4. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
5. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olazepine beats risperidone, risperidone beats quetiapine, and quetiapine beats olazepine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
6. Safer DJ. Design and reporting modifications in industry sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002;190:583-92.
7. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
8. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008;299:1813-7.
9. Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration, 2011.
10. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
11. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;343:d7202.
12. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database Syst Rev 2013;12:ED000075.
13. White J, Bero LA. Corporate manipulation of research: strategies are similar across five industries. Stanford Law Policy Rev 2010;21:105-34.